Identification

Name
Efavirenz
Accession Number
DB00625  (APRD00059, DB07709)
Type
Small Molecule
Groups
Approved, Investigational
Description

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Structure
Thumb
Synonyms
  • (-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
  • (S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
  • (S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
  • 6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
  • Efavirenz
  • Éfavirenz
  • Efavirenzum
External IDs
DMP 266 / L 743726
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-efavirenzTablet600 mgOralAuro Pharma Inc2014-03-03Not applicableCanada
Mylan-efavirenzTablet600 mgOralMylan Pharmaceuticals2013-07-30Not applicableCanada
StocrinTablet, film coated600 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinCapsule50 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinTablet, film coated200 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinCapsule200 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinSolution30 mg/mlOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinTablet, film coated50 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinCapsule100 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
StocrinCapsule200 mgOralMerck Sharp & Dohme Limited1999-05-28Not applicableEu
International/Other Brands
E.F (McNeil & Argus) / Efavir (Cipla) / Efavirenz (Aspen Pharmacare) / Efcure (Emcure Pharmaceuticals) / Efferven (Ranbaxy Laboratories) / Estiva (Hetero) / Evirenz (Alkem Laboratories) / Stocrin (Merck & Co.) / Viranz (Aurobindo Pharma)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-efavirenz-emtricitabine-tenofovirEfavirenz (600 mg) + Emtricitabine (200 mg) + Tenofovir disoproxil fumarate (300 mg)TabletOralApotex CorporationNot applicableNot applicableCanada
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralLake Erie Medical Dba Quality Care Produts Llc2006-07-202017-09-16Us
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralDoh Central Pharmacy2009-07-01Not applicableUs
AtriplaEfavirenz (600 mg) + Emtricitabine (200 mg) + Tenofovir disoproxil fumarate (300 mg)TabletOralBristol Myers Squibb & Gilead Sciences, Llc2007-10-23Not applicableCanada
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralRemedy Repack2017-03-20Not applicableUs
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralA S Medication Solutions2006-07-202017-06-20Us
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2012-10-16Not applicableUs
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralAvera Mc Kennan Hospital2015-03-06Not applicableUs
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralBristol Myers Squibb & Gilead Sciences, Llc2006-07-20Not applicableUs
AtriplaEfavirenz (600 mg/1) + Emtricitabine (200 mg/1) + Tenofovir disoproxil fumarate (300 mg/1)Tablet, film coatedOralA S Medication Solutions2006-07-20Not applicableUs
Categories
UNII
JE6H2O27P8
CAS number
154598-52-4
Weight
Average: 315.675
Monoisotopic: 315.027390859
Chemical Formula
C14H9ClF3NO2
InChI Key
XPOQHMRABVBWPR-ZDUSSCGKSA-N
InChI
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
IUPAC Name
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one
SMILES
FC(F)(F)[[email protected]]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1

Pharmacology

Indication

For use in combination treatment of HIV infection (AIDS)

Structured Indications
Pharmacodynamics

Efavirenz (dideoxyinosine, ddI) is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.

Mechanism of action

Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.

TargetActionsOrganism
AReverse transcriptase/RNaseH
inhibitor
Human immunodeficiency virus 1
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

99.5-99.75%

Metabolism

Efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1.

Route of elimination

Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites.

Half life

40-55 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategory
Efavirenz Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2B6CYP2B6*6Not AvailableG > T / A > GEffect Directly StudiedThe presence of this polymorphism in CYP2B6 is associated with reduction in efavirenz metabolism.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Efavirenz.Experimental
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Efavirenz.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Efavirenz.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Efavirenz.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Efavirenz.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Efavirenz.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Efavirenz.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Efavirenz.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Efavirenz.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Efavirenz.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Efavirenz is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Efavirenz.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Efavirenz.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Efavirenz.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Efavirenz.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Efavirenz.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Efavirenz.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Efavirenz.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Efavirenz.Approved, Illicit, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Efavirenz.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Efavirenz.Approved, Withdrawn
AmiodaroneThe metabolism of Efavirenz can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Efavirenz.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Efavirenz.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Efavirenz.Approved, Illicit
AmodiaquineEfavirenz may increase the hepatotoxic activities of Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Efavirenz.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Efavirenz.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Efavirenz.Experimental
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Efavirenz.Approved
AmrinoneThe serum concentration of Amrinone can be decreased when it is combined with Efavirenz.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Efavirenz.Approved
ApixabanThe metabolism of Apixaban can be decreased when combined with Efavirenz.Approved
AprepitantThe serum concentration of Efavirenz can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Efavirenz.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Efavirenz.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Efavirenz.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Efavirenz.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Efavirenz.Approved, Investigational
AtomoxetineThe metabolism of Efavirenz can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Efavirenz.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Efavirenz.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Efavirenz.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Efavirenz.Investigational, Vet Approved
AzelastineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe serum concentration of Azelnidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
AzimilideThe serum concentration of Azimilide can be decreased when it is combined with Efavirenz.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Efavirenz.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Efavirenz.Illicit
BarnidipineThe serum concentration of Barnidipine can be decreased when it is combined with Efavirenz.Approved
BencyclaneThe serum concentration of Bencyclane can be decreased when it is combined with Efavirenz.Experimental
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Efavirenz.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Efavirenz.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Efavirenz.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Efavirenz.Approved
BepridilThe serum concentration of Bepridil can be decreased when it is combined with Efavirenz.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Efavirenz.Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Efavirenz.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Efavirenz.Approved, Withdrawn
BortezomibThe metabolism of Efavirenz can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Efavirenz.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Efavirenz.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Efavirenz is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Efavirenz.Approved, Investigational
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Efavirenz.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Efavirenz.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efavirenz.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Efavirenz.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Efavirenz.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Efavirenz.Approved, Investigational
BuprenorphineThe serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Efavirenz.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Efavirenz.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Efavirenz.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Efavirenz.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Efavirenz.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Efavirenz.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Efavirenz.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.Approved, Illicit, Vet Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Efavirenz.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Efavirenz.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Efavirenz.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Efavirenz.Approved
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Efavirenz.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Efavirenz.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Efavirenz.Investigational
CarbamazepineThe metabolism of Efavirenz can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe serum concentration of Carboxyamidotriazole can be decreased when it is combined with Efavirenz.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Efavirenz.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Efavirenz.Approved
CaroverineThe serum concentration of Caroverine can be decreased when it is combined with Efavirenz.Experimental
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Efavirenz.Approved, Investigational
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Efavirenz.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Efavirenz.Approved, Investigational
CeritinibThe serum concentration of Efavirenz can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Efavirenz.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Efavirenz.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Efavirenz.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Efavirenz.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Efavirenz.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Efavirenz.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Efavirenz.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Efavirenz.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Efavirenz.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Efavirenz.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Efavirenz.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Efavirenz.Approved
CilnidipineThe serum concentration of Cilnidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Efavirenz.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Efavirenz.Approved, Vet Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Efavirenz.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Efavirenz.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Efavirenz.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Efavirenz.Approved
ClemastineThe metabolism of Efavirenz can be decreased when combined with Clemastine.Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Efavirenz.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Efavirenz.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Efavirenz.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Efavirenz.Experimental
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Efavirenz resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Efavirenz.Approved, Illicit
ClorindioneThe serum concentration of Clorindione can be decreased when it is combined with Efavirenz.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Efavirenz.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Efavirenz.Approved, Illicit
ClotrimazoleThe metabolism of Efavirenz can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Efavirenz.Approved
CobicistatThe metabolism of Efavirenz can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Efavirenz.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Efavirenz.Approved, Illicit
ConivaptanThe serum concentration of Efavirenz can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Efavirenz can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Efavirenz.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Efavirenz.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Efavirenz.Approved
DabrafenibThe serum concentration of Efavirenz can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dantrolene.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Efavirenz.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Efavirenz.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dapoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Efavirenz.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be decreased when it is combined with Efavirenz.Experimental
DarunavirThe serum concentration of Efavirenz can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Efavirenz.Approved
DasatinibThe serum concentration of Efavirenz can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Efavirenz can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Efavirenz can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Efavirenz.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Efavirenz.Approved
DesipramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desloratadine.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Efavirenz.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Efavirenz.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Efavirenz.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Efavirenz.Approved, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Efavirenz.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efavirenz.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Efavirenz.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Efavirenz.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Efavirenz.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Efavirenz.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Efavirenz.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Efavirenz.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Efavirenz.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Efavirenz.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Efavirenz.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Efavirenz.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Efavirenz.Experimental
DihydroergotamineThe metabolism of Efavirenz can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efavirenz.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efavirenz.Experimental, Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Efavirenz.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dimenhydrinate.Approved
DiphenadioneThe serum concentration of Diphenadione can be decreased when it is combined with Efavirenz.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Efavirenz.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efavirenz.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Efavirenz.Experimental
DoconexentThe metabolism of Doconexent can be decreased when combined with Efavirenz.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Efavirenz.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Efavirenz.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Efavirenz.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Efavirenz.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Efavirenz.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Efavirenz.Approved
DotarizineThe serum concentration of Dotarizine can be decreased when it is combined with Efavirenz.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Efavirenz.Approved
DoxepinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Doxepin.Approved
DoxorubicinThe metabolism of Efavirenz can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Efavirenz can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Efavirenz.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Illicit
DronedaroneThe metabolism of Efavirenz can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Efavirenz.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Efavirenz.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Efavirenz.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Efavirenz.Investigational
EfonidipineThe serum concentration of Efonidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Efavirenz.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Efavirenz.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Efavirenz.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Efavirenz.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Efavirenz.Approved, Investigational, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Efavirenz.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Efavirenz can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe serum concentration of Eperisone can be decreased when it is combined with Efavirenz.Approved, Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Efavirenz.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Efavirenz.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Efavirenz.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Efavirenz.Approved, Investigational
ErythromycinThe metabolism of Efavirenz can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Efavirenz.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Efavirenz.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Efavirenz.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Efavirenz.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Efavirenz.Approved
EthanolThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Efavirenz.Approved
EthotoinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Efavirenz.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Efavirenz.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Efavirenz.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Efavirenz.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Efavirenz.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Efavirenz.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Efavirenz.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Efavirenz.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Efavirenz.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Efavirenz.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Efavirenz.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Efavirenz.Illicit, Vet Approved
EtravirineThe serum concentration of Efavirenz can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Efavirenz.Approved
EzogabineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ezogabine.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Efavirenz.Approved
FelbamateThe risk or severity of adverse effects can be increased when Efavirenz is combined with Felbamate.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Efavirenz.Approved, Illicit, Withdrawn
FendilineThe serum concentration of Fendiline can be decreased when it is combined with Efavirenz.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Efavirenz.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Efavirenz.Experimental
FluconazoleThe metabolism of Efavirenz can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Efavirenz.Approved, Illicit
FluindioneThe serum concentration of Fluindione can be decreased when it is combined with Efavirenz.Investigational
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Efavirenz.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Efavirenz.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Efavirenz.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Efavirenz.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Efavirenz.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Efavirenz.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Efavirenz.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Efavirenz.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Efavirenz.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Efavirenz.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Efavirenz.Approved
FluvoxamineThe metabolism of Efavirenz can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Efavirenz.Approved, Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Efavirenz resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Efavirenz can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Efavirenz can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Efavirenz.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Efavirenz can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Efavirenz.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Efavirenz is combined with Gabapentin Enacarbil.Approved
GallopamilThe serum concentration of Gallopamil can be decreased when it is combined with Efavirenz.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Efavirenz.Approved, Illicit, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Efavirenz.Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Efavirenz.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Efavirenz.Approved, Investigational
Ginkgo bilobaThe serum concentration of Efavirenz can be decreased when it is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GliclazideThe metabolism of Gliclazide can be decreased when combined with Efavirenz.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Efavirenz.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Efavirenz.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Efavirenz.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Efavirenz.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Efavirenz.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Efavirenz.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Efavirenz.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Efavirenz.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Efavirenz.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Efavirenz.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Efavirenz.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Efavirenz.Approved, Investigational
HydrocodoneEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Efavirenz.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Efavirenz.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Efavirenz.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Efavirenz.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Iloperidone.Approved
ImatinibThe metabolism of Efavirenz can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Efavirenz.Approved
IndalpineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Efavirenz.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Efavirenz.Investigational
indisulamThe metabolism of indisulam can be decreased when combined with Efavirenz.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Efavirenz.Approved, Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Efavirenz.Approved, Investigational
IsavuconazoniumThe metabolism of Efavirenz can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Efavirenz.Approved, Vet Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Efavirenz.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
IvacaftorThe serum concentration of Efavirenz can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Efavirenz.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Efavirenz.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Efavirenz.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Efavirenz.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Efavirenz.Approved, Vet Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Efavirenz.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Efavirenz.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Efavirenz.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Efavirenz.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Efavirenz.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Efavirenz.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efavirenz.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Efavirenz.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Efavirenz.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efavirenz.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Efavirenz.Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Efavirenz.Approved, Vet Approved
LidoflazineThe serum concentration of Lidoflazine can be decreased when it is combined with Efavirenz.Experimental
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Efavirenz.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Efavirenz.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Efavirenz.Illicit
LoperamideThe metabolism of Loperamide can be decreased when combined with Efavirenz.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Efavirenz.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Efavirenz.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Efavirenz.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Efavirenz.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Efavirenz.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Efavirenz.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Efavirenz.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.Approved
LuliconazoleThe serum concentration of Efavirenz can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Efavirenz can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Efavirenz.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Efavirenz.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Efavirenz.Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Efavirenz.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Efavirenz.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Vet Approved
ManidipineThe serum concentration of Manidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Efavirenz.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Efavirenz.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Efavirenz.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Efavirenz.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Efavirenz.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Efavirenz.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Efavirenz.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Efavirenz.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Efavirenz.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Efavirenz.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Efavirenz.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Efavirenz.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Efavirenz.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Efavirenz.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Efavirenz.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Efavirenz.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Efavirenz.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Efavirenz.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Efavirenz.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Efavirenz.Approved
MethotrimeprazineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Efavirenz.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Efavirenz.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Efavirenz.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Efavirenz.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Efavirenz.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Efavirenz.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Efavirenz.Approved
MetyrosineEfavirenz may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Efavirenz.Experimental
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Efavirenz.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Efavirenz.Approved, Illicit
MifepristoneThe serum concentration of Efavirenz can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Efavirenz is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
MirtazapineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Efavirenz can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Efavirenz.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Efavirenz.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Efavirenz.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Efavirenz.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Efavirenz.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Efavirenz.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
NaftopidilThe serum concentration of Naftopidil can be decreased when it is combined with Efavirenz.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efavirenz.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Efavirenz.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Efavirenz.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Efavirenz.Approved, Investigational
NefazodoneThe metabolism of Efavirenz can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Efavirenz can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Efavirenz can be increased when it is combined with Netupitant.Approved
NevirapineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Efavirenz.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Efavirenz.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.Approved
NiguldipineThe serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.Experimental
NilotinibThe metabolism of Efavirenz can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be decreased when it is combined with Efavirenz.Experimental
NilutamideThe metabolism of Nilutamide can be decreased when combined with Efavirenz.Approved
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Efavirenz.Approved, Investigational
NimesulideThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Efavirenz.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Efavirenz.Approved, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Efavirenz.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Efavirenz.Investigational
NorgestimateThe serum concentration of the active metabolites of Norgestimate can be reduced when Norgestimate is used in combination with Efavirenz resulting in a loss in efficacy.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Efavirenz.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Efavirenz.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Efavirenz.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Efavirenz.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Efavirenz.Approved, Investigational
OlaparibThe metabolism of Efavirenz can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Efavirenz.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Olopatadine.Approved
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Efavirenz.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Efavirenz.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Efavirenz.Approved, Illicit
OrphenadrineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Efavirenz.Investigational
OsimertinibThe serum concentration of Efavirenz can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Efavirenz.Approved
OtiloniumThe serum concentration of Otilonium can be decreased when it is combined with Efavirenz.Experimental, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Efavirenz.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Efavirenz.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Efavirenz.Approved, Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Efavirenz.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Efavirenz.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Efavirenz.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Efavirenz.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efavirenz.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Efavirenz.Approved, Vet Approved
PalbociclibThe serum concentration of Efavirenz can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Efavirenz.Approved
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Efavirenz.Approved
ParaldehydeEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Efavirenz.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Efavirenz.Approved
ParoxetineThe metabolism of Efavirenz can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Efavirenz.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Efavirenz.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Efavirenz.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.Approved, Vet Approved
PentobarbitalThe metabolism of Efavirenz can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Efavirenz.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Efavirenz.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Efavirenz.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Efavirenz.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Efavirenz.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Efavirenz.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Efavirenz.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Efavirenz.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Efavirenz.Experimental
PhenindioneThe serum concentration of Phenindione can be decreased when it is combined with Efavirenz.Approved, Investigational
PhenobarbitalThe metabolism of Efavirenz can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Efavirenz.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Efavirenz.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Efavirenz.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Efavirenz.Approved, Vet Approved
PhenytoinThe serum concentration of Efavirenz can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Efavirenz.Approved
PinaveriumThe serum concentration of Pinaverium can be decreased when it is combined with Efavirenz.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Efavirenz.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Efavirenz.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Efavirenz.Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Efavirenz.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Efavirenz.Approved
PizotifenThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pizotifen.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Efavirenz.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Efavirenz.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
PramipexoleEfavirenz may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Efavirenz.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Efavirenz.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Efavirenz.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Efavirenz.Approved, Vet Approved
PregabalinThe serum concentration of Pregabalin can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational
PrenylamineThe serum concentration of Prenylamine can be decreased when it is combined with Efavirenz.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Efavirenz.Approved
PrimidoneThe metabolism of Efavirenz can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Efavirenz.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Efavirenz.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Efavirenz.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Efavirenz.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Efavirenz.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Efavirenz.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Efavirenz.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Efavirenz.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Efavirenz.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Efavirenz.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Efavirenz.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Efavirenz.Investigational
QuazepamThe serum concentration of Efavirenz can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Efavirenz.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Efavirenz.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Efavirenz.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Efavirenz.Experimental
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Efavirenz.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Efavirenz.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ramelteon.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Efavirenz.Approved
RanolazineThe metabolism of Efavirenz can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efavirenz.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Efavirenz.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Efavirenz.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Efavirenz.Approved
RifampicinThe serum concentration of Efavirenz can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Efavirenz can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Efavirenz.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Efavirenz.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Efavirenz.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Efavirenz.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Efavirenz.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Efavirenz.Investigational, Withdrawn
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Efavirenz.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Efavirenz.Vet Approved
RopiniroleEfavirenz may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Efavirenz.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Efavirenz.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Efavirenz.Approved
RotigotineEfavirenz may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Efavirenz.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Efavirenz.Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Efavirenz.Approved, Vet Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Efavirenz.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Efavirenz.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Efavirenz.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Efavirenz.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Efavirenz.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Efavirenz.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Efavirenz.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Efavirenz.Approved, Vet Approved
SildenafilThe metabolism of Efavirenz can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Efavirenz can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Efavirenz can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Efavirenz.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Efavirenz.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Efavirenz.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
SorafenibThe metabolism of Efavirenz can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Efavirenz can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Efavirenz can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efavirenz.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Efavirenz.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Efavirenz.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Efavirenz.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Efavirenz.Approved
SulfisoxazoleThe metabolism of Efavirenz can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Efavirenz.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Efavirenz.Experimental
SuprofenThe metabolism of Suprofen can be decreased when combined with Efavirenz.Approved, Withdrawn
SuvorexantEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Efavirenz.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Efavirenz.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tasimelteon.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Efavirenz.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Efavirenz.Approved, Withdrawn
TelithromycinThe metabolism of Efavirenz can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Efavirenz.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Efavirenz.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Efavirenz.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Efavirenz.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Efavirenz.Experimental
TerodilineThe serum concentration of Terodiline can be decreased when it is combined with Efavirenz.Experimental
TestosteroneThe metabolism of Testosterone can be decreased when combined with Efavirenz.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Efavirenz.Approved, Vet Approved
TetrahydropalmatineThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Efavirenz.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Efavirenz.Investigational
ThalidomideEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Efavirenz.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Efavirenz.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Efavirenz.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Efavirenz.Approved, Withdrawn
ThiotepaThe metabolism of Efavirenz can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Efavirenz.Approved
TiagabineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Efavirenz.Approved, Investigational
TiclopidineThe metabolism of Efavirenz can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Efavirenz.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Efavirenz.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Efavirenz.Approved
TioclomarolThe serum concentration of Tioclomarol can be decreased when it is combined with Efavirenz.Experimental
TipranavirThe metabolism of Tipranavir can be decreased when combined with Efavirenz.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Efavirenz.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Efavirenz.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.Approved, Withdrawn
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Efavirenz.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Efavirenz.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.Approved
TorasemideThe metabolism of Torasemide can be decreased when combined with Efavirenz.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Efavirenz.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Efavirenz.Approved, Investigational
TranilastThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Efavirenz.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Efavirenz.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Efavirenz.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Efavirenz.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Efavirenz.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Efavirenz.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Efavirenz.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Efavirenz.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Efavirenz.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Efavirenz.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Efavirenz.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Efavirenz.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Efavirenz.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Efavirenz.Investigational, Withdrawn
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Efavirenz.Approved, Investigational, Nutraceutical
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Efavirenz.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Efavirenz.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Efavirenz.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Efavirenz.Approved, Investigational
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Efavirenz.Approved
VenlafaxineThe metabolism of Efavirenz can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Efavirenz.Experimental
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Efavirenz.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vigabatrin.Approved
VinpocetineThe serum concentration of Vinpocetine can be decreased when it is combined with Efavirenz.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Efavirenz.Experimental
VismodegibThe metabolism of Vismodegib can be decreased when combined with Efavirenz.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Efavirenz.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Efavirenz.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Efavirenz.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Efavirenz.Experimental
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Efavirenz.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Efavirenz.Vet Approved
XylometazolineThe serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Efavirenz.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Efavirenz.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Efavirenz.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Efavirenz.Approved, Investigational
ZiconotideThe serum concentration of Ziconotide can be decreased when it is combined with Efavirenz.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Efavirenz.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Efavirenz.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Efavirenz can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Efavirenz.Vet Approved
ZolpidemEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Efavirenz.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Efavirenz.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Efavirenz.Approved, Investigational
Food Interactions
  • Avoid excessive or chronic alcohol consumption.
  • Take without regard to meals.

References

Synthesis Reference

John Doney, "Amorphous efavirenz and the production thereof." U.S. Patent US20070026073, issued February 01, 2007.

US20070026073
General References
  1. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5. Epub 2002 Oct 17. [PubMed:12386343]
External Links
Human Metabolome Database
HMDB14763
KEGG Drug
D00896
KEGG Compound
C08088
PubChem Compound
64139
PubChem Substance
46506827
ChemSpider
57715
BindingDB
2483
ChEBI
119486
ChEMBL
CHEMBL223228
Therapeutic Targets Database
DAP000709
PharmGKB
PA449441
HET
EFZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Efavirenz
ATC Codes
J05AR06 — Emtricitabine, tenofovir disoproxil and efavirenzJ05AG03 — EfavirenzJ05AR11 — Lamivudine, tenofovir disoproxil and efavirenz
AHFS Codes
  • 08:18.08.16 — Nonnucleoside Reverse Transcriptase Inhibitors
PDB Entries
1fk9 / 1fko / 1ikv / 1ikw / 1jkh / 4b3o
FDA label
Download (154 KB)
MSDS
Download (57.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedOtherHealthy Volunteers1
1CompletedNot AvailableDrug Abuse / Human Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHIV-infection/Aids1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Protease Inhibitors1
1CompletedBasic ScienceDrug Interactions / Intestinal Transporter Expression / Pharmacodynamics / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceTuberculosis1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticHuman Volunteers1
1CompletedHealth Services ResearchHuman Immunodeficiency Virus (HIV) Infections1
1CompletedOtherHIV-DDI1
1CompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentContraception / Human Immunodeficiency Virus (HIV) Infections / Pharmacokinetics1
1CompletedTreatmentHIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers / Infections, Human Immunodeficiency Virus and Herpesviridae1
1CompletedTreatmentHepatic Impairment / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHepatitis C Virus (HCV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Tumors, Solid1
1CompletedTreatmentTuberculosis1
1RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1SuspendedTreatmentHuman Immunodeficiency Virus (HIV)1
1Unknown StatusNot AvailableHealthy Volunteers1
1Unknown StatusNot AvailableHuman Immunodeficiency Virus (HIV) / Hyperlipidemias1
1Unknown StatusTreatmentCytochrome P-450 CYP2B6 / Efavirenz / Human Immunodeficiency Virus (HIV)1
1, 2CompletedTreatmentAcute HIV Infection1
1, 2CompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV)1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1, 2CompletedTreatmentInfection, Human Immunodeficiency Virus I / Pf Subclinical Parasitemia1
2Active Not RecruitingTreatmentAcute HIV Infection / HIV CNS Involvement1
2Active Not RecruitingTreatmentContraception / Human Immunodeficiency Virus (HIV)1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHIV Seropositivity1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAntiretroviral Naive / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentContraception / Human Immunodeficiency Virus (HIV)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections25
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)2
2CompletedTreatmentInfection, Human Immunodeficiency Virus I4
2TerminatedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
2TerminatedTreatmentInfection, Human Immunodeficiency Virus I1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2Unknown StatusTreatmentProstate Cancer1
2WithdrawnTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
2, 3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2, 3Not Yet RecruitingTreatmentSeverely Immunocompromised HIV Patients1
2, 3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus-type 1 Infection1
3Active Not RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
3Active Not RecruitingTreatmentInfection, Human Immunodeficiency Virus I / Kaposi s Sarcoma (KS)1
3CompletedNot AvailableAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
3CompletedScreeningHuman Immunodeficiency Virus (HIV)1
3CompletedScreeningHuman Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections2
3CompletedTreatmentHIV-infection/Aids / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHIV/TB Co-infection1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections30
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1)2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
3CompletedTreatmentInfection, Human Immunodeficiency Virus I3
3RecruitingTreatmentInfection, Human Immunodeficiency Virus I2
3RecruitingTreatmentInfection, Human Immunodeficiency Virus I / Tuberculosis1
3SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3WithdrawnPreventionBreastfeeding / Human Immunodeficiency Virus (HIV) Infections / Pregnancy1
4Active Not RecruitingNot AvailableDrug Interactions1
4Active Not RecruitingPreventionInfection, Human Immunodeficiency Virus I1
4Active Not RecruitingTreatmentHepatitis C, Chronic / Human Immunodeficiency Virus (HIV) Infections1
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
4CompletedDiagnosticCardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome1
4CompletedDiagnosticHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4CompletedPreventionCentral Nervous System Diseases / Dementias / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
4CompletedTreatmentAcute HIV Infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentCardiovascular Disease (CVD)1
4CompletedTreatmentHCV Coinfection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)6
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections11
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I2
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)2
4CompletedTreatmentInfection, Human Immunodeficiency Virus I2
4Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections2
4RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
4RecruitingSupportive CareHuman Immunodeficiency Virus (HIV)1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mitochondrial Dysfunction1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis3
4Unknown StatusBasic ScienceHuman Immunodeficiency Virus (HIV)1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections5
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4WithdrawnTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableActive Not RecruitingTreatmentAnti-Retroviral Agents / Dyslipidemias / Efavirenz / HIV-1-infection / Rilpivirine / Sustained Virologic Response1
Not AvailableCompletedNot AvailableBreastfeeding / Human Immunodeficiency Virus (HIV) / Pregnancy1
Not AvailableCompletedNot AvailableCD4 Cell Counts / Treatment Failure, HIV or AIDS1
Not AvailableCompletedNot AvailableDrug Effects1
Not AvailableCompletedNot AvailableHIV-infection/Aids1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV)2
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedBasic ScienceHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedScreeningEfavirenz, Metabolism and Pharmacokinetics Changes1
Not AvailableCompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentAcute HIV Infection1
Not AvailableCompletedTreatmentAntiretroviral Treatment Outcomes1
Not AvailableCompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections12
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis2
Not AvailableCompletedTreatmentSleep disorders and disturbances1
Not AvailableNo Longer AvailableNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableRecruitingNot AvailableChild Behavior / Cognitive Symptom / Drug-Related Side Effects and Adverse Reactions / Efavirenz / Medication Adherence1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Tuberculosis1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableUnknown StatusPreventionHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Immune Reconstitution Inflammatory Syndrome1
Not AvailableUnknown StatusTreatmentHBV Coinfection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculous Meningitis1
Not AvailableWithdrawnBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1

Pharmacoeconomics

Manufacturers
  • Bristol myers squibb co
  • Bristol myers squibb pharma co
Packagers
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
SolutionOral30 mg/ml
Tablet, film coatedOral200 mg
Tablet, film coatedOral50 mg
Tablet, film coatedOral600 mg
Capsule, gelatin coatedOral200 mg/1
Capsule, gelatin coatedOral50 mg/1
Tablet, film coatedOral600 mg/1
CapsuleOral100 mg
CapsuleOral200 mg
CapsuleOral50 mg
TabletOral600 mg
Prices
Unit descriptionCostUnit
Sustiva 600 mg tablet21.68USD tablet
Sustiva 200 mg capsule7.37USD capsule
Sustiva 100 mg capsule3.34USD capsule
Sustiva 50 mg capsule1.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5811423No1992-08-072012-08-07Us
CA2279198No2009-04-142018-02-02Canada
CA2101572No2001-08-282013-07-29Canada
US5914331Yes1998-01-022018-01-02Us
US6043230Yes1998-01-252018-01-25Us
US5814639Yes1997-03-292017-03-29Us
US6555133Yes1999-10-062019-10-06Us
US6939964Yes1998-07-202018-07-20Us
US6639071Yes1998-08-142018-08-14Us
US6238695Yes1999-10-062019-10-06Us
US6642245Yes2001-05-042021-05-04Us
US6703396Yes2001-09-092021-09-09Us
US5922695Yes1998-01-252018-01-25Us
US5935946Yes1998-01-252018-01-25Us
US5977089Yes1998-01-252018-01-25Us
US8592397No2004-01-132024-01-13Us
US8716264No2004-01-132024-01-13Us
US9018192No2006-06-132026-06-13Us
US8598185No2008-05-012028-05-01Us
US9545414No2006-06-132026-06-13Us
US9457036No2004-01-132024-01-13Us
US9744181No2004-01-132024-01-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)139-141 °CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00855 mg/mLALOGPS
logP3.89ALOGPS
logP4.46ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)12.52ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.34 m3·mol-1ChemAxon
Polarizability26.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9182
Caco-2 permeable+0.5553
P-glycoprotein substrateNon-substrate0.7617
P-glycoprotein inhibitor INon-inhibitor0.7451
P-glycoprotein inhibitor IINon-inhibitor0.9557
Renal organic cation transporterNon-inhibitor0.9157
CYP450 2C9 substrateNon-substrate0.8033
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6037
CYP450 1A2 substrateInhibitor0.6996
CYP450 2C9 inhibitorNon-inhibitor0.6975
CYP450 2D6 inhibitorNon-inhibitor0.8699
CYP450 2C19 inhibitorNon-inhibitor0.5291
CYP450 3A4 inhibitorNon-inhibitor0.7577
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6705
Ames testNon AMES toxic0.6991
CarcinogenicityNon-carcinogens0.8997
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9617
hERG inhibition (predictor II)Non-inhibitor0.9098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-1059000000-f599b397bafd1974176e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-5090000000-b807e6fcee57f8b27cb6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9040000000-260d9ba8c55987cd2b0e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9010000000-459e48522e8275e941f8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-531ef8f962aff7837863
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-9574533b450f3724a645
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03dl-0098000000-f0d050ef36094b37e62d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fxx-0091000000-8ab690a60877e8476640
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0frx-0190000000-deeefb25f97b767955b2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0giu-0390000000-7a682b484377bc11de1b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01b9-0790000000-a789e578dcf6568d7eb9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0930000000-a1dae29a53e6be48d87f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014r-0910000000-70a86e64f2e50ce28b18
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00xu-0390000000-d7561e61b30a86d9a480
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0giu-1290000000-c402be3d2864520be5fb

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxazines
Sub Class
Not Available
Direct Parent
Benzoxazines
Alternative Parents
Ynones / Benzenoids / Aryl chlorides / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organofluorides / Organochlorides
show 2 more
Substituents
Benzoxazine / Aryl chloride / Aryl halide / Ynone / Benzenoid / Oxacycle / Propargyl-type 1,3-dipolar organic compound / Organic 1,3-dipolar compound / Azacycle / Hydrocarbon derivative
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, organochlorine compound, cyclopropanes, acetylenic compound, benzoxazine (CHEBI:119486)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72547
Uniprot Name
Reverse transcriptase/RNaseH
Molecular Weight
65223.615 Da
References
  1. Gazzard BG: Efavirenz in the management of HIV infection. Int J Clin Pract. 1999 Jan-Feb;53(1):60-4. [PubMed:10344069]
  2. Adkins JC, Noble S: Efavirenz. Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. [PubMed:9878993]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100-2. [PubMed:11159797]
  3. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459]
  2. Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18